Replies to post #14192 on Aurinia Pharmaceuticals Inc (AUPH)

[Optionsrbest4u]

Hope You are Right with Revision of buy out...

WS seems to be guessing otherwise though. I was hoping for short drop to near that Max Pain figure of $24 for an opportunity to load up more shares - not looking likely at this point anyway.

[Jesspro]

We all play musical estimate so why not. Anything over 55 is a bonus. But PG knows the value of Voclosporin for other indications including FSGS, DES, cyclosporine treated diseases and flirtation with SLE and other immunological diseases. A big pharma is the only one that could exploit these points of light. PG is not giving it away for chump change.

[Zeppo]

I agree with you on ramping up a potential buy-out price a bit. Why? I just watched the interview with the BMY CEO. He outlined the product categories that were in early stages of clinical trials. Those trials are, collectively, going to cost billions. He also noted 85 ongoing collaborations with other biotech/pharma concerns. Many of those alliances also will cost a lot of money, because BMY, with its deep pockets, will be funding clinical trials. Yes, AUPH is off the beaten path for BMY, but BMY may not be able to afford to let go of a potential revenue stream of this magnitude from a company with an approved product that will no longer cost time and resources for more trials.

[Ganz]

Giovanni’s reaction was about as telling as it gets,and more importantly, he had the perfect chance to quell the BO rumors and he didn’t.
And Purea, welcome to party pal, your BO revision is righteous buddy.